Domestic launch status of Novartis’ targeted drug Apelvis

In the medical field, the targeted drug Alpelisib (Alpelisib) developed by Novartis Pharmaceuticals has received widespread attention as an important drug for the treatment of breast cancer. This is a targeted therapeutic drug targeting PIK3CA gene mutations. It inhibits the growth and spread of breast cancer cells by inhibiting the PI3K signaling pathway. At present, Apelvis has been approved by the FDA in the United States and has achieved significant therapeutic effects in clinical practice. However, in the country, the listing process of Apelis is still in the review stage.

Currently, domestic clinical research on Apelvis is ongoing. Many medical institutions and experts are actively exploring the effectiveness of this drug on domestic patients. Although this drug has not yet been officially launched in China, its successful international application experience provides us with valuable reference.

For patients who are in urgent need of Apelvis, they may consider purchasing the drug overseas. There are currently different versions of the drug in overseas markets. The European original research version produced by Novartis is slightly more expensive, priced at more than 40,000 per box. There is also an original Indian version produced by Novartis, which sells for about 5,000 per box. In addition, in Laos, there is a generic version produced by Lucius Pharmaceuticals, which costs about 2,500 per box.

It is worth noting that the therapeutic effect of Apelvis is closely related to the patient's genotype. Only patients with PIK3CA gene mutations can benefit from this drug. Therefore, before receiving treatment, patients need to undergo genetic testing to determine whether they are suitable for Apelvis.

In general, the domestic launch of Novartis' targeted drug Apelvis needs to wait for further news. Patients with treatment needs can consider purchasing drugs overseas, but be sure to choose formal channels. At the same time, we hope that relevant domestic departments can speed up the approval process so that more patients can benefit from the treatment of this drug as soon as possible.